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Aims/hypothesis. ADP-ribosyl-cyclase activity (ADPRCA) of CD38 and other ectoenzymes mainly generate cyclic adenosine
5’diphosphate-(ADP-) ribose (cADPR) as a second messenger in various mammalian cells, including pancreatic beta cells and
peripheral blood mononuclear cells (PBMCs). Since PBMCs contribute to the pathogenesis of diabetic nephropathy, ADPRCA
of PBMCs could serve as a clinical prognostic marker for diabetic nephropathy. This study aimed to investigate the connection
between ADPRCA in PBMCs and diabetic complications. Methods. PBMCs from 60 diabetic patients (10 for type 1 and 50
for type 2) and 15 nondiabetic controls were ﬂuorometrically measured for ADPRCA based on the conversion of nicotinamide
guanine dinucleotide (NGD
+) into cyclic GDP-ribose. Results. ADPRCA negatively correlated with the level of HbA1c (P = .040,
R2 = .073), although ADPRCA showed no signiﬁcant correlation with gender, age, BMI, blood pressure, level of fasting plasma
glucose and lipid levels, as well as type, duration, or medication of diabetes. Interestingly, patients with nephropathy, but
not other complications, presented signiﬁcantly lower ADPRCA than those without nephropathy (P = .0198) and diabetes
(P = .0332). ANCOVA analysis adjusted for HbA1c showed no signiﬁcant correlation between ADPRCA and nephropathy.
However, logistic regression analyses revealed that determinants for nephropathy were systolic blood pressure and ADPRCA, not
HbA1c. Conclusion/interpretation. Decreased ADPRCA signiﬁcantly correlated with diabetic nephropathy. ADPRCA in PBMCs
would be an important marker associated with diabetic nephropathy.
Copyright © 2008 Michio Ohtsuji et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Diabetes mellitus is characterized by chronic hyperglycemia
and the development of diabetes-speciﬁc microvascular
complications. As a consequence of these complications,
diabetes is a leading cause of end stage renal disease
(ESRD)[1].Actually,diabetic nephropathyisthesinglemost
common cause of ESRD in Japan [2]. Recent epidemiologic
data indicated that the number of Japanese type 2 diabetic
patients on renal replacement therapy has tripled within
less than 15 years, and Japanese type 2 diabetic patients
might be particularly predisposed to nephropathy [3, 4].
Therefore, earlier detection of high-risk Japanese subjects
for the diabetic nephropathy is quite important for early
intervention to prevent ESRD.
Chronic low-grade inﬂammation and activation of the
innate immune system are closely involved in the patho-
genesis of diabetes and its microvascular complications [5,
6]. Inﬂammatory events are central to the pathogenesis of
diabetic nephropathy [7–9], and inﬂammatory cytokines
are involved in its development and progression [10].
Macrophages derived from circulating monocytes have been
recently focused on as playing central roles in the pro-
gression of diabetic nephropathy [11, 12]. Since PBMCs2 Experimental Diabetes Research
mainly consist of lymphocytes and monocytes, both of
which contribute to the progression of diabetic nephropathy,
intracellular regulatory signals involved in the activation of
PBMCs could serve as a possible therapeutic target and/or
clinical prognostic marker for diabetic nephropathy.
Cyclic adenosine 5’diphosphate-ribose (cADPR) plays
a second messenger role in a variety of mammalian cells,
including pancreatic beta cells, kidney mesangial cells, and
PBMCs [13]. The rapid release of Ca2+ from the smooth
endoplasmic reticulum (SER), the most characterized Ca2+
organelle, is evoked by stimulation of two kinds of receptors
on the SER for ryanodine and inositol (1,4,5)-triphosphate.
cADPR is catalyzed from beta-NAD+ by ADP-ribosyl-
cyclase activity (ADPRCA) of CD38, CD157, and other
ectocellular membrane-bound enzymes [14–18]. cADPR
has been recently demonstrated to stimulate a variety of
mammaliancellfunctions,includingproliferation,secretion,
contraction, and vasodilation [19–25]. For example, several
studies have examined ADPRCA in kidney mesangial cells
[26, 27], and cADPR has been reported to induce smooth
muscle contraction in small renal arteries [28].
Since cADPR modulates adaptive immune recognition
process of PBMCs [29], we hypothesized that impaired
regulatory signals of ADPRCA in PBMCs would result in
the progression of diabetic vascular complications. However,
no clinical studies have been performed to examine the
relationship between CD38 and diabetic complications.
Based on this background, this study investigates the
connection between ADPRCA in PBMCs and diabetic
vascular complications, especially nephropathy.
2. MATERIALS AND METHODS
2.1. Studypopulation
Patients were eligible for the study if they exhibited diabetes
mellitus. Diabetes mellitus was diagnosed and classiﬁed
according to World Health Organization (WHO) criteria
[30,31].Subjectswithotherendocrinediseasesorsigniﬁcant
renal and/or hepatic diseases were excluded. The study,
approved by the ethics committee of Kanazawa University
Graduate School of Medical Science, was conducted in
accordance with the Declaration of Helsinki (1964), and all
patients gave written informed consent before participating
in the study.
Deﬁnitionofdiabeticcomplications
ssessment and diagnosis of diabetic complications were
performed as below [32]. Nephropathy was diagnosed as
the existence of albuminuria, proteinuria, and/or creati-
nine clearance <60mL/min. Albuminuria was deﬁned as
urinary albumin excretion between 20 and 200mg/24hr
or urinary albumin to urinary creatinine ratio between
30 and 300mg/gCr. Proteinuria was deﬁned as Albustix
[Ames] positive. Creatinine clearance values were calculated
by the Cockroft-Gault formula. Retinopathy was diagnosed
on the basis of direct ophthalmoscopy (through a dilated
pupil) by an experienced ophthalmologist and/or by ﬂu-
orescein angiography. Peripheral neuropathy was assessed
by questioning patients about symptoms of neuropathy,
including paresthesia, dulled sensation, and pain in legs
and feet and was based on clinical examination (i.e.,
measuring abnormal knee/ankle reﬂexes and a Semmes-
Weinsteinmonoﬁlament)andconﬁrmedbymeasurementof
conduction velocities of ulnar (motor and sensory), tibial,
peroneal, and sural nerves. Macroangiopathy was considered
in subjects who met the following three conditions: (1)
a history of a cardiovascular event and/or the presence
of angina and/or permanent ischemic electrocardiogram
abnormalitiesatrestorischemicabnormalitiesinastresstest
(usually combined with a cardiac noninvasive imaging tech-
nique); (2) claudication and/or abolished peripheral pulses
and/or foot lesions due to vascular disease demonstrated
by Doppler echography and/or angiography; or (3) carotid
vascular disease, as assessed by Doppler echography.
Medicationfordiabetes
Medication for type 2 diabetics was classiﬁed into three
categories:dietarytherapywithoutmedication,insulininjec-
tion, and oral hypoglycemic agents including sulphonylureas
and alpha-glucosidase inhibitors. No type 2 diabetic subjects
being treated with insulin sensitizers (including thiazolidine-
diones and biguanides) were enrolled in this study.
2.2. Laboratorymeasurements
Body mass index (BMI) was calculated as weight (in
kilograms) divided by height (in meters) squared. Venous
blood samples were obtained after a 12-hour overnight
fast. Blood glucose was measured with the glucose oxidase
method and HbA1c by high-pressure liquid chromatogra-
phy. Serum total cholesterol (TC) and triglycerides (TG)
were determined by enzymatic methods, and high-density
lipoprotein cholesterol (HDL-C) levels were measured by a
polyanion-polymer/detergent method. Low-density lipopro-
tein cholesterol(LDL-C)wascalculatedusing the Friedewald
formula.
2.3. MeasurementofADPRCA
IsolationofPBMCmembranousfraction
After obtaining written informed consent, peripheral blood
samples were collected. PBMCs were isolated using Ficoll-
P a q u eP L U S( S i g m a )[ 33–35] and centrifuged. Isolated
PBMCsweresuspendedin10mMTris/HClsolution,pH7.4,
with 5mM MgCl2 (2 mL for each sample) at 4◦Cf o r3 0
minutes. The suspension was homogenized in a Teﬂon-glass
homogenizer; the resultant homogenate was centrifuged at
4◦C for 5 minutes at 1000×gt or e m o v eu n b r o k e nc e l l s
and nuclei. Crude membrane fractions were prepared by
centrifugation (twice) of homogenates at 105000×gf o r1 5
minutes. The supernatant was removed, and precipitates
weresuspendedin10mMTris/HClsolution,pH6.7[36,37].Michio Ohtsuji et al. 3
For each experiment, membranes were freshly prepared and
used immediately for enzymatic reactions.
FluorometricmeasurementofADP-ribosylcyclaseactivity
ADPRCAwasdeterminedﬂuorometricallyusingatechnique
based on measurement of the conversion of β-NGD+ into
the ﬂuorescent product cGDP-ribose [36–39]. In brief,
2.5mL of reaction mixtures containing 60μM β-NGD+,
50mM Tris/HCl, pH 6.6, 100mM KCl, 10μMC a C l 2,a n d
membranes (62–297μg of protein) were maintained at 37◦C
under constant stirring. The samples were then excited
at 300nm, and ﬂuorescence emission was continuously
monitored at 410nm in a Shimadzu RF-5300PC spectroﬂu-
orophotometer (Kyoto, Japan). Activity was calculated from
thedatapointsrecordedduring5minutespermgmembrane
protein as reported previously [37].
2.4. Statisticalanalysis
All data are shown as mean ± SD. Continuous variables
were compared by one-way analyses of variance (ANOVA)
or covariance (ANCOVA) after being adjusted for age, BMI,
and sex. Normality of the distribution of Ln(ADPRCA) was
conﬁrmed by Shapiro-Wilk’s W-test. Diﬀerences between
the two groups were compared by chi2 analysis (categorical
variables) or nonparametric Mann-Whitney U-test (contin-
uous variables). Logistic regression analyses were performed
to clarify the clinical parameters contributing to categorical
variables. Stepwise multivariate regression analyses were
performed to clarify the clinical parameters contributing to
the level of continuous variable. All statistical analyses were
conducted with JMP 6.03 for Macintosh OS-X 10.5 (SAS
Institute Inc, Cary, NC, USA). A P-value of less than .05 was
considered statistically signiﬁcant.
3. RESULTS
RelationshipbetweenADPRCAandclinicalparameters
In total, sixty Japanese diabetic patients (31 males and 29
females) and ﬁfteen nondiabetic controls (6 males and 9
females) were enrolled in this study. The baseline char-
acteristics of the subjects are shown in Table 1. ADPRCA
showed statistically signiﬁcant negative correlation with
the level of HbA1c (P = .040, R2 = 0.073, Figure 1). As
shown in Table 2, no signiﬁcant correlation was observed
between ADPRCA and other clinical parameters (level of
fasting plasma glucose, systolic and diastolic blood pressure,
serum total cholesterol, logarithm of serum TG, HDL-C,
LDL-C, age, duration of diabetes, BMI, gender diﬀerence,
type of diabetes (Figure 2(a)), or medication for diabetes
(Figure 2(b))).
ADPRCAinindividualswithdiabeticcomplications
Figure 3 shows the relationship between ADPRCA and
the diabetic vascular complications. ADPRCA was signif-
icantly lower in subjects with nephropathy than those
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Figure 1: ADP-ribosyl cyclase activities and the level of HbA1c.
StatisticallysigniﬁcantrelationshipwasobservedbetweenADPRCA
and HbA1c (P = .040, R2 = 0.073, Ln(ADPRC) =3.4277567–
0.093904∗HbA1c).
without (P = .0198) and nondiabetic controls (P = .0332)
(Figure 3(a)). Subjects with other complications also showed
similar tendencies; however, no signiﬁcant correlations
betweenADPRCAandretinopathy,neuropathy,ormacroan-
giopathy were observed (Figures 3(b)–3(d)). Although
HbA1c level showed relationship with ADPRCA, no signif-
icant diﬀerence was observed in ADPRCA between subjects
with any diabetic complications (data not shown).
As HbA1c was signiﬁcantly related to ADPRCA, we
examined whether HbA1c contributed to the relationship
betweenADPRCAandnephropathy.TheresultsofANCOVA
showed that the diﬀerence just failed to meet statistical
signiﬁcance after adjusting for HbA1c (Table 3). Next,
to examine whether ADPRCA could be an independent
contributor to the existence of nephropathy, we performed
logisticanalysesadjustedforsystolicbloodpressure,diastolic
blood pressure, TG, HDL, LDL, gender, type of diabetes,
duration of diabetes, medication for diabetes, HbA1c, and
BMI. Systolic blood pressure and ADPRCA contributed
signiﬁcantly to the existence of nephropathy (Table 4).
4. DISCUSSION
The main ﬁnding of this study was that diabetic subjects
with nephropathy showed decreased ADPRCA. However,
PBMCs in proinﬂammatory states like diabetic vasculopathy
might be relating to increased ADPRCA as several cytokines
including IL-8, IFN-gamma upregulate intracellular CD38
activity [17], our results interestingly showed decreased
ADPRCA in PBMCs. Logistic analysis revealed that only
systolic blood pressure and ADPRCA, but not HbA1c, were
signiﬁcantly related to the incidence of nephropathy. There-
fore, contribution of HbA1c to the relationship between
ADPRCA and nephropathy should be considered small
in extent. ADPRCA’s correlation with nephropathy seems
reasonable.4 Experimental Diabetes Research
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Figure 2: (a) ADP-ribosyl cyclase activities and type of diabetes. No signiﬁcant relationship was observed between ADPRCA and type of
diabetes. (b) ADP-ribosyl cyclase activities and medication for type 2 diabetes. No signiﬁcant relationship was observed between ADPRCA
and medication for type 2 diabetes. CTL: control; OHA: oral hypoglycemic agent.
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Figure 3: Relationship between logarithm of ADP-ribosyl-cyclase activity Ln(ADPRCA) and diabetic vascular complications. Figures show
relationship between nondiabetic control, subjects with each complication, and those without. (a) Subjects with nephropathy showed lower
ADPRCA than those without nephropathy (P = .0198) and nondiabetic controls (P = .0332). (b)–(d) No signiﬁcant diﬀerence in ADPRCA
was observed in subjects with retinopathy, neuropathy, and macroangiopathy. CTL: control.Michio Ohtsuji et al. 5
Table 1: Baseline characteristics of subjects. Results are expressed as mean ± S.D.
Type 1 diabetes Type 2 diabetes Nondiabetic control
Number of subjects 10 50 15
Gender (male/female) 5/5 26/24 6/9
Age (years) 36.0 ± 14.26 3 .0 ±12.05 1 .0 ±22.0
BMI (kg/m2)2 1 .4 ±2.62 2 .9 ±3.92 2 .1 ±2.4
Duration of diabetes (years) 11.0 ±9.21 6 .0 ±9.7—
Fasting plasma glucose (mg/dl) 244 ± 130 164 ± 54 81 ± 12
HbA1c (%) 8.0 ± 1.57 .6 ±1.34 .6 ±0.7
Medication for diabetes
Diet alone — 4 —
Oral hypoglycemic agents — 30 —
Insulin 10 16 —
Diabetic complications
Nephropathy 3 20
Retinopathy 4 22
Neuropathy 4 25
Macroangiopathy 0 18
ADP-ribosyl cyclase activity (nmol/min/mg protein) 16.9 ±7.51 6 .6 ±7.61 7 .8 ±4.6
Table 2: Correlation of ADP-ribosyl-cyclase activity with subject
parameters (calculated with logarithm-transformed TG).
Factor R2 P-value
Fasting plasma glucose 0.0120 NS
HbA1c 0.0731 .040
Systolic blood pressure 0.0133 NS
Diastolic blood pressure 0.0301 NS
Total cholesterol (TC) 0.0424 NS
HDL-C 0.0042 NS
LDL-C 0.0258 NS
Triglyceride (TG) 0.0588 NS
Duration of diabetes 0.0150 NS
Age 0.0367 NS
BMI 0.0174 NS
Gender 0.0151 NS
Table 3: Comparison of ADPRCA inﬂuence on nephropathy,
adjusted for HbA1c.
Factor Average S.E. 95% C.I. P-value
Nephropathy (−) 2.799 0.076 2.646–2.951 .075
Nephropathy (+) 2.576 0.095 2.386–2.765
First, to discuss the role of cADPR-mediated signals in
PBMCs, since ADPRCA could be stimulated by angiotensin-
II [37], kidney tissue with diabetic nephropathy could show
increased ADPRCA. Recent report by Kim et al. showed
increased ADPRCA in the kidney of STZ-induced diabetes
mice[18].AswemeasuredADPRCAinPBMCs,thisdiscrep-
ancy could be acceptable. Interestingly, the roles of CD38 on
PBMCs’eﬀectonvascularcomplicationsarebidirectional.In
Table 4: Logistic analysis between nephropathy and parameters
in diabetic subjects. Carrier of complication = 1, noncarrier = 0;
medication: insulin =2, OHA = 1, diet = 0; gender: male = 1,
female = 0; type of diabetes: type 2 =1, type 1 = 0.
Factor Regression coeﬃcient R2 P-value
Systolic blood pressure −0.09115 6.040 .0140
ADP-ribosyl-cyclase activity 2.61758 3.707 .0229
PBMCs, binding of agonistic anti-CD38 antibodies, which
stimulate ADPRCA, induces release of proinﬂammatory
cytokines including IL-1, IL-6, and TNF-alpha over the short
term [40]. Cytokine release could make an important con-
tribution to inﬂammation responsible in the early stages of
diabeticvascularcomplications.Ontheotherhand,agonistic
CD38 ligation inhibits cell growth and induces apoptosis
in B-cell precursors [41] mediating phosphatidylinositol 3-
kinase signaling [42], although having stimulatory eﬀects
on mature lymphocytes. The suppressive eﬀect mediated by
CD38 was also observed in experiments with patient-derived
myeloid leukemia cells and with the murine cell line [43]. In
addition, CD38 expression has been reported in circulating
monocytes but not in resident macrophages and dendritic
cells [44, 45]. Diﬀerentiation of monocytes to macrophages
resultedinthedownregulationofsurfaceexpressionofCD38
[46]. CD38 is strongly expressed in lymphocyte precursors,
declined during diﬀerentiation, and then upregulated again
in mature plasma cells [47]. CD157 was suggested to display
a similar expression tendency in myeloid cells [48]. Since
hyperglycemia directly enhances protein ADP-ribosylation
in cultured neuroblastoma cells [49], resulting in increased
ADPRCA in diabetic subjects, we speculate that decreased
ADPRCA in PBMCs could reﬂect decreased suppressive6 Experimental Diabetes Research
eﬀects of CD38 and CD157 and increased numbers of
diﬀerentiated cells.
Second, let us consider the agonistic eﬀects of autoan-
tibodies against CD38, which is shown to exert insulin
secretion from cultured human islets [50] through ADPRCA
activation. In humans, the majority of anti-CD38 autoanti-
bodies (∼60%) display agonistic properties [51, 52], which
demonstrate the capability to trigger Ca2+ release in lym-
phocytic cell lines [53]. In agreement with these functional
features, the presence of anti-CD38 autoantibodies in type
2 diabetic patients was associated with signiﬁcantly higher
levels of fasting plasma C-peptide and insulin, as compared
with anti-CD38 negative subjects. Thus, anti-CD38 autoim-
munity might indicate a relative protection against beta-
cell failure and a lower risk of insulin requirement [52, 54,
55]. Previous reports on the clinical characteristics of anti-
CD38 autoantibodies carriers have not gone into depth on
diabetic complications, although the possible exacerbation
of diabetic complications by the agonistic eﬀect of anti-
CD38 autoantibodies on PBMCs was noted by Mallone et
al. [51]. However, several discussions should be needed for
the relationship between CD38 autoantibodies and diabetic
vasculopathy as agonistic CD38 autoantibodies possibly
stimulate both insulin rsecretion resulting in hyperinsuline-
mia, the prominent risk factor for diabetic macroangiopathy,
and angiotensin-II induced renal artery contraction. We just
speculate that those with anti-CD38 autoantibodies should
show lower frequencies of diabetic nephropathy, and other
vascular complications in long-term follow-up studies due
to better glycemic control and increased ADPRCA reﬂecting
less maturated PBMCs.
Third, as all of our subjects were diabetic, it behooves
us mention the Okamoto model of diabetes pathogenesis.
CD38-related signal has been well documented in dia-
b e t e sm e l l i t u s[ 18, 56–58]. Our results showing decreased
ADPRCA being signiﬁcantly correlated to increased HbA1c
is compatible with previous studies reﬂecting to some degree
the Okamoto model [59–61]. Interestingly, in our study,
no signiﬁcant relationship was observed between ADPRCA
and fasting plasma glucose. We suggest that ADPRCA
might be more related to postprandial than fasting plasma
glucose level, the former being strongly responsive to insulin
secretion [27, 29].
Finally, the clinical signiﬁcance of our results: CD38
expression, representative of ADP-ribosyl cyclase, is already
used clinically as a prognostic marker for HIV infected
subjects [62, 63] and chronic lymphoid leukemia (CLL)
[13, 56, 64]. Since other ADP ribosyl cyclases including
CD157 reside on the cell surface of PBMCs, restricting
examination to CD38 would not entirely cover cADPR-
mediated signaling impairment. Measuring ADPRCA would
thus be a better approach in ﬂagging up groups at risk
for diabetic nephropathy from among general diabetic
subjects.WeenvisionADPRCAmeasurementbeingsimilarly
introduced into clinical settings for detecting subjects at
high-risk for diabetic nephropathy and thus prompting early
intervention to prevent ESRD.
This study had a number of limitations. First, we did
not have data on anti-CD38 autoantibodies. ADPRCA in
each subject is partly determined by preexisting factors inde-
pendentofdiabetes, including CD38 geneticpolymorphisms
and autoantibodies against CD38. We speculate that higher
ADPRCA values might reﬂect possession of anti-CD38
autoantibodies. Second, we did not examine any markers of
lymphocyte or monocyte maturation/diﬀerentiation. Both
should be examined in further studies.
In conclusion, our ﬁndings suggest that decreased
ADPRCA in PBMCs is signiﬁcantly correlated with diabetic
nephropathy and that measurement of ADPRCA in PBMCs
could serve as an important marker associated with diabetic
nephropathy. Further prospective studies should be intro-
duced to clarify the mechanism and predictive signiﬁcance
of decreased ADPRCA in diabetic complications.
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